Chimerix (CMRX) Drastic Slump; Axiom Capital Sees Upside in Amazon (AMZN)


Shares of Chimerix, Inc. (Nasdaq:CMRX) slumped more than 70% to touch an all-time low in pre-market trade Monday after the company said that a Phase 3 trial evaluating its antiviral brincidofovir in patients undergoing hematopoietic cell transplantation has failed to meet the primary endpoint.

CMRX stock closed at $35.57, down $0.21 (or -0.59%), and 156,097 of its shares exchanged hands during the last trading session

Chimerix, a biopharmaceutical company, 46.15M Shares Outstanding. At close on Thursday, the company had a Market Capitalization $1.64B and CMRX stock 52-week range was from $33.02 to $58.04 per share



Brokerage firm Axiom Capital raised its price target on, Inc. (Nasdaq:AMZN) shares from $727.00 to $797.00, while maintaining a Buy rating

The internet retailer company reported record-breaking holiday season for Amazon Prime, Amazon Original Series and Amazon devices

AMZN stock finished Thursday’s trading session at $662.79 with a total of 1,092,970 shares traded during the day has 468.76M Shares Outstanding, Market Capitalization (intraday) of $310.69B and AMZN stock one-year range is between $285.25 and $684.82 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at